Remove Clinical Trials Remove Pharmaceutical Remove Sleep
article thumbnail

Tryp Therapeutics Announces Phase 2a Clinical Trial for Fibromyalgia with the University of Michigan

Cannabis Law Report

The study is expected to be the world’s first Phase 2a clinical trial evaluating the efficacy of psilocybin and psychotherapy to treat fibromyalgia. The open-label Phase 2a clinical trial will evaluate the efficacy of TRYP-8802, an oral formulation of synthetic psilocybin, in tandem with psychotherapy for treating fibromyalgia.

article thumbnail

Could CBN really help you sleep? Consumer study data suggest yes.

The Cannigma

CBN has made headlines and claimed shelf space as the next best cannabinoid for sleep. MoreBetter, creators of the Releaf App, is using this real world data to push back against the claim that there’s no evidence that CBN can help people sleep. It also, allegedly, helps with sleep (more on that below). Back to our study.

Sleep 135
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Trouble Sleeping: Cannabis for Insomnia Relief

MMJ Recs

Many patients are turning to cannabis for insomnia relief, seeking its potential to improve sleep quality and duration. Insomnia is a common sleep disorder characterized by difficulty falling asleep, staying asleep, or experiencing non-restorative sleep despite having the opportunity to sleep.

Sleep 111
article thumbnail

IGC Completes Cohort 2 of its Phase 1 THC-Based Clinical Trial on Alzheimer’s Patients

Cannabis Law Report

IGC”) (NYSE American: IGC) announces today that it has completed Cohort 2 of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”)-based investigational new drug, IGC-AD1, intended to alleviate the symptoms of individuals suffering from Alzheimer’s disease. This Phase 1 trial is currently testing IGC-AD1 for safety.

article thumbnail

Medical Marijuana is Being Used to Treat Dementia With Success

FloridaMarijuana.net

Pharmaceutical treatments for for Dementia often only target symptoms like pain or depression, but those medicines do not cure or prevent the disease. The clinical trials for medications take years and to this date, there have been no effective medications to properly treat and/or cure Dementia.

article thumbnail

Incannex (ASX: IHL) partners with Procaps to develop cannabis medicine for clinical trial on sleep apnea

Cannabis Law Report

Incannex Healthcare Limited (ASX: IHL) has engaged pharmaceutical manufacturing company Procaps S.A The agreement between the two companies will see Procaps making IHL-42X for Incannex’s Phase 2, Phase 3, and open-label clinical trials. According to an article from the Lancet, sleep apnea affects 936 million adults globally.

article thumbnail

Chanelle McCoy Granted Approval For Significant Ultra Pure Synthetic CBD Phase III Efficacy Clinical Trial

Cannabis Law Report

PRESS RELEASE UK company Chanelle McCoy Health granted Ethics Approval to commence Phase III Efficacy Clinical Trial for the treatment of Sleep Disturbance CMH-CBD-001 using their Ultra Pure Synthetic Cannabinoid (CBD) formulation with pharmaceutical grade FDA registered raw material.